Martínez J C, Piris M A, Sánchez-Beato M, Villuendas R, Orradre J L, Algara P, Sánchez-Verde L, Martínez P
Department of Pathology, Instituto Oftálmico (SRS-CAM), Toledo, Spain.
J Pathol. 1993 Apr;169(4):405-12. doi: 10.1002/path.1711690404.
The retinoblastoma susceptibility gene (Rb) has been characterized as a tumour suppressor gene. Rb protein is involved in cell-cycle control, regulating gene transcription. The absence of Rb protein in inherited retinoblastoma has been proved to be the result of inactivation of both Rb alleles through mutation or deletion, according to the general model for suppressor genes. The frequent detection of Rb gene alterations in human tumours (retinoblastoma, osteosarcoma, bladder carcinoma, small-cell lung carcinoma) and the correlation with clinical outcome found in some tumours prompted us to study Rb gene expression in lymphoid tumours in an attempt to determine whether Rb gene expression is related to histological type and degree of aggressivity in human lymphomas. To establish normal levels of Rb protein, its expression was analysed in vitro on cytospin preparations from normal and pokeweed mitogen (PWM) or phytohaemagglutinin (PHA)-stimulated peripheral blood lymphocytes (PBLs), using a monoclonal antibody (PMG3-245). Rb protein expression in vivo was quantified using a computer analysis system (CAS) on frozen sections from reactive and neoplastic lymphoid tissue. As a control of tissue preservation, and to compare Rb expression and growth fraction, the tumours and cells were labelled simultaneously with the Ki67 monoclonal antibody. Normal and stimulated lymphocytes showed a gradual increase of Rb protein during progression of the cell cycle, with a peak in the M phase. G0-G1 cells had no detectable levels of Rb protein, suggesting that the Rb gene may act as a 'status quo' cellular growth fraction control mechanism. In reactive lymphoid tissue, Rb protein was mainly expressed in germinal centres (lymph nodes, tonsils) and cortical thymocytes.(ABSTRACT TRUNCATED AT 250 WORDS)
视网膜母细胞瘤易感基因(Rb)已被鉴定为一种肿瘤抑制基因。Rb蛋白参与细胞周期调控,调节基因转录。根据抑癌基因的一般模型,遗传性视网膜母细胞瘤中Rb蛋白的缺失已被证明是由于两个Rb等位基因通过突变或缺失而失活的结果。人类肿瘤(视网膜母细胞瘤、骨肉瘤、膀胱癌、小细胞肺癌)中Rb基因改变的频繁检测以及在某些肿瘤中发现的与临床结果的相关性促使我们研究Rb基因在淋巴瘤中的表达,以确定Rb基因表达是否与人类淋巴瘤的组织学类型和侵袭程度相关。为了确定Rb蛋白的正常水平,使用单克隆抗体(PMG3 - 245)在来自正常和经商陆有丝分裂原(PWM)或植物血凝素(PHA)刺激的外周血淋巴细胞(PBL)的细胞涂片制剂上体外分析其表达。使用计算机分析系统(CAS)对反应性和肿瘤性淋巴组织的冰冻切片进行体内Rb蛋白表达定量。作为组织保存的对照,并为了比较Rb表达和生长分数,肿瘤和细胞同时用Ki67单克隆抗体标记。正常和受刺激的淋巴细胞在细胞周期进展过程中显示Rb蛋白逐渐增加,在M期达到峰值。G0 - G1期细胞未检测到Rb蛋白水平,这表明Rb基因可能作为一种“维持现状”的细胞生长分数控制机制。在反应性淋巴组织中,Rb蛋白主要表达于生发中心(淋巴结、扁桃体)和皮质胸腺细胞。(摘要截短于250字)